SMAD2 and central nervous system cancer: Furthermore, decreased PFS and OS correlate with elevated concentrations of the substrate of TGF-β receptor I (TβRI), phosphorylated SMAD2 (p-SMAD2), in contrast to the concentrations in glioma patients with lower levels [164,169].